Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: High dietary salt Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

NCT00808093
View directory record Official record
Conditions
Dyslipidaemias
Interventions
GSK256073
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 28, 2026, 6:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

NCT05627635
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
Interventions
Balstilimab, Bevacizumab, Biospecimen Collection, Botensilimab, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, X-Ray Imaging
Biological · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

NCT04628767
View directory record Official record
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Pegfilgrastim, Therapeutic Conventional Surgery, Vinblastine Sulfate
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
257
States / cities
Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 197 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Acute Dietary Sodium on Cerebrovascular Reactivity and Blood Pressure Reactivity

NCT03564262
View directory record Official record
Conditions
Blood Pressure, Cerebrovascular Reactivity
Interventions
Low Sodium Meal (138 mg sodium), High Sodium Meal (1,495 mg sodium)
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional

Comparison of MMFS Dosages in Older Adults

NCT03601169
View directory record Official record
Conditions
Anxiety, Depression, Sleep Quality, Cognitive Impairment
Interventions
Low Dose MMFS-205-SR, High Dose MMFS-205-SR, Placebo
Dietary Supplement
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans

NCT00872599
View directory record Official record
Conditions
Hypertension
Interventions
fenofibrate, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Dietary Salt on Post-exercise Hypotension

NCT03565653
View directory record Official record
Conditions
Blood Pressure, Post-Exercise Hypotension
Interventions
High dietary salt, Placebo
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Phase 1 Interventional

Sorafenib in Treating Patients With Advanced Solid Tumors

NCT00436579
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sorafenib tosylate, pharmacological study, assessment of therapy complications, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
14 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2014 · Synced Sep 28, 2026, 6:12 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

NCT05761171
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Month to 6 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Biobehavioral Impact of Diet Quality on Affect and Craving

NCT04105712
View directory record Official record
Conditions
Food Addiction, Withdrawal
Interventions
Dietary Change (low in highly processed foods)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 40 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 28, 2026, 6:12 PM EDT
Withdrawn Phase 1Phase 2 Interventional

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

NCT03563170
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Interventions
ETBX-011, GI-4000, haNK for infusion, avelumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, SBRT, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, Cetuximab, N-803
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional

Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate

NCT03234361
View directory record Official record
Conditions
Hypertension
Interventions
High Phosphate Phase, Low Phosphate Phase
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

Topical Naloxone to Diagnose Ocular Pain

NCT04454281
View directory record Official record
Conditions
Dry Eye Syndromes, Neuropathic Pain
Interventions
Naloxone Hydrochloride 0.4 MG/ML
Drug
Lead sponsor
Seema Capoor
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 28, 2026, 6:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Salt Study: Inhibited Breathing Pattern and Sodium Inhibitors in Sodium Sensitivity of Blood Pressure

NCT00800228
View directory record Official record
Conditions
Hypertension
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
40 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Effect of ACT and Float REST on Burnout Syndrome.

NCT03535493
View directory record Official record
Conditions
Burnout Syndrome
Interventions
Acceptance and Commitment Therapy (ACT), Float REST, ACT + Float REST
Behavioral
Lead sponsor
Amrinder Babbra
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Saint Charles, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

NCT01187901
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Erlotinib, Sulindac, Placebo A, Placebo B
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 69 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes

NCT01076829
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
Spice polyphenols
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Sep 28, 2026, 6:12 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Dietary Sodium, Oxidative Stress, and Pulsatile Hemodynamics

NCT04233957
View directory record Official record
Conditions
Sodium Excess
Interventions
High Sodium, Placebo
Dietary Supplement · Other
Lead sponsor
University of Delaware
Other
Eligibility
21 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)

NCT01585402
View directory record Official record
Conditions
Arterial Calcification, CD73 Deficiency
Interventions
Etidronate, MRI Scan
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NCT03126916
View directory record Official record
Conditions
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 30 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
152
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Product Messages for Colombia

NCT04567004
View directory record Official record
Conditions
Obesity
Interventions
Control, Nutriscore Label, Adapted Peruvian Nutrient Label, Guideline Daily Amount Label
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
8,071 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ketone Ester and Salt (KEAS) in Young Adults

NCT05545501
View directory record Official record
Conditions
Salt; Excess, Hypertension
Interventions
No Salt, No β-OHB, High Salt, No β-OHB, High Salt, High β-OHB
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
19 Years to 39 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Completed No phase listed Observational

HER Salt Lake Initiative

NCT02734199
View directory record Official record
Conditions
Birth Control, Contraception
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
4,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 28, 2026, 6:12 PM EDT